Expects Humira access in U.S will continue to decrease through 2H25 as more plans choose exclusionary formularies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Morning Movers: Roblox skyrockets following second quarter results
- AbbVie raises FY25 revenue view to $60.5B from ~$59.7B, consensus $60.01B
- AbbVie raises FY25 adjusted EPS view to $11.88-$12.08 from $11.67-$11.87
- AbbVie reports Q2 adjusted EPS $2.97, consensus $2.91
- Options Volatility and Implied Earnings Moves Today, July 31, 2025